--- title: "Tvardi Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295924692.md" datetime: "2026-08-14T11:07:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295924692.md) - [en](https://longbridge.com/en/news/295924692.md) - [zh-HK](https://longbridge.com/zh-HK/news/295924692.md) generator: "portal-rs" --- # Tvardi Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.69, missing the estimate of USD -0.625. EBIT: As of FY2026 Q2, the actual value is USD -6.457 M. ### Operating Expenses - **Research and development expenses** for the three months ended June 30, 2026, were $4.0 million, a decrease from $5.8 million for the comparable period in 2025. For the six months ended June 30, 2026, these expenses were $8.913 million, compared to $8.917 million for the same period in 2025. - **General and administrative expenses** were $2.6 million for the three months ended June 30, 2026, a decrease from $3.1 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, these expenses were $4.767 million, an increase from $4.306 million for the same period in 2025. - **Total operating expenses** for the three months ended June 30, 2026, were $6.629 million, down from $8.869 million in the comparable 2025 period. For the six months ended June 30, 2026, total operating expenses were $13.680 million, an increase from $13.223 million for the same period in 2025. ### Net (Loss) Income - **Loss from operations** for the three months ended June 30, 2026, was - $6.629 million, an improvement from - $8.869 million in the comparable 2025 period. For the six months ended June 30, 2026, loss from operations was - $13.680 million, compared to - $13.223 million for the same period in 2025. - **Interest income** was $0.172 million for the three months ended June 30, 2026, compared to $0.377 million in the comparable 2025 period. For the six months ended June 30, 2026, interest income was $0.419 million, compared to $0.652 million for the same period in 2025. - **Other income, net** was $0 million for the three months ended June 30, 2026, compared to $12.659 million in the comparable 2025 period. For the six months ended June 30, 2026, other income, net was $0 million, compared to $7.159 million for the same period in 2025. - **Net loss** for the three months ended June 30, 2026, was - $6.457 million, compared to a net income of $4.167 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, net loss was - $13.261 million, compared to - $5.412 million for the same period in 2025. ### Cash Position - **Cash, cash equivalents and short-term investments** were $15.8 million as of June 30, 2026, a decrease from $30.8 million as of December 31, 2025. ### Balance Sheet (in thousands) - **Total current assets** as of June 30, 2026, were $17,069, down from $31,538 as of December 31, 2025. - **Total assets** as of June 30, 2026, were $17,517, compared to $32,073 as of December 31, 2025. - **Total current liabilities** as of June 30, 2026, were $9,113, compared to $11,042 as of December 31, 2025. - **Total liabilities** as of June 30, 2026, were $9,135, compared to $11,127 as of December 31, 2025. - **Total stockholders’ equity** as of June 30, 2026, was $8,382, compared to $20,946 as of December 31, 2025. ### Operational Metrics and Developments - Tvardi Therapeutics, Inc. reported topline results from the healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, confirming its prodrug design, improved tolerability, and pharmacodynamic evidence of STAT3 target engagement. - TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and reductions in cellular and humoral immune populations. - Ulcerative Colitis (UC) has been selected as the initial disease indication for TTI-109, representing a large, underserved market with over 1.25 million patients diagnosed in the U.S. and an addressable market of approximately $3 billion in the U.S. and $9 billion globally. ### Outlook and Guidance - Tvardi Therapeutics, Inc. anticipates its existing cash, cash equivalents, and short-term investments will fund operations through the TTI-101 HCC topline readout into the third quarter of 2027. - Key upcoming milestones include a KOL webinar on August 19, 2026, and topline data for TTI-101 Phase 1b/2 HCC in Q4 2026. - The initiation of a clinical trial for TTI-109 in UC is planned for 2027, subject to Investigational New Drug (IND) application clearance and additional funding. ### Related Stocks - [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md) ## Related News & Research - [Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million](https://longbridge.com/en/news/295925308.md) - [TTI files HKEX next-day disclosure return on share repurchase for cancellation](https://longbridge.com/en/news/298573114.md) - [TTI files HKEX next-day disclosure return reporting share repurchase cancellation](https://longbridge.com/en/news/298715658.md) - [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md) - [LOG Commercial Properties publishes financial calendar update for 2026](https://longbridge.com/en/news/298951880.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**